Therapy of renal cell carcinoma with interleukin-2 and lymphokine-activated killer cells: phase II experience with a hybrid bolus and continuous infusion interleukin-2 regimen.
Forty-seven patients with metastatic or unresectable renal cell carcinoma were treated with interleukin-2 (IL-2) and lymphokine-activated killer (LAK)-cell therapy, using a hybrid IL-2 regimen. IL-2 was administered initially by intravenous bolus (10(5) U/kg [Cetus Corp, Emeryville, CA] every 8 hours for 3 days) during the priming phase, and subsequently by continuous infusion (3 x 10(6) U/m2 for 6 days); during this second treatment period, in vitro-generated LAK cells were administered. Despite selection of patients for good performance status (PS) (29, PS 0; 18, PS 1) prior nephrectomy (43 of the 47 patients), and low tumor burden, the response rate was low (two complete [CRs] and two partial responses [PRs], for an overall objective response rate of 9%). Toxicity was comparable to that experienced with the high-dose bolus regimen. These results suggest that the dose and schedule of IL-2 administration may influence the likelihood of response to IL-2 in renal cell carcinoma.
Parkinson
D R
DR
National Cancer Institute IL-2/LAK Extramural Working Group, National Cancer Institute, Bethesda, MD 20892.
Fisher
R I
RI
Rayner
A A
AA
Paietta
E
E
Margolin
K A
KA
Weiss
G R
GR
Mier
J W
JW
Sznol
M
M
Gaynor
E R
ER
Bar
M H
MH
D000328:Adult; D001002:Anuria / Q000209:etiology; D002292:Carcinoma, Renal Cell / Q000628:therapy*; D004334:Drug Administration Schedule; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D007022:Hypotension / Q000209:etiology; D016219:Immunotherapy, Adoptive; D007262:Infusions, Intravenous / Q000379:methods; D007376:Interleukin-2 / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use; D007680:Kidney Neoplasms / Q000628:therapy*; D015979:Killer Cells, Lymphokine-Activated / Q000637:transplantation*; D008297:Male; D008875:Middle Aged; D012074:Remission Induction
D007376:Interleukin-2